Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 9:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–17 of 17 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: AC220 Clear all
Completed Phase 3 Interventional Results available

(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive

NCT02039726
View directory record Official record
Conditions
AML
Interventions
Quizartinib, Salvage Chemotherapy
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
36
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2021 · Synced Sep 2, 2026, 9:11 PM EDT
Completed Phase 1 Interventional

A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML)

NCT01390337
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
AC220, daunorubicin, cytarabine
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 60 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
5
States / cities
Jacksonville, Florida • Chicago, Illinois • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2019 · Synced Sep 2, 2026, 9:11 PM EDT
Completed Phase 1 Interventional Results available

A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status

NCT00462761
View directory record Official record
Conditions
Acute Myeloid Leukemia, Leukemia, Myelodysplastic Syndrome, AML, MDS
Interventions
AC220
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
3
States / cities
Birmingham, Alabama • Omaha, Nebraska • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 10, 2020 · Synced Sep 2, 2026, 9:11 PM EDT
Recruiting Phase 1Phase 2 Interventional

Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

NCT04047641
View directory record Official record
Conditions
Acute Myeloid Leukemia, Blasts 20 Percent or More of Bone Marrow Nucleated Cells, High Risk Myelodysplastic Syndrome, Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent High Risk Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory High Risk Myelodysplastic Syndrome
Interventions
Cladribine, Cytarabine, Idarubicin, Quizartinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 2, 2026, 9:11 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

NCT01892371
View directory record Official record
Conditions
FLT3 Gene Mutation Negative, FLT3 Internal Tandem Duplication Positive, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic Syndrome
Interventions
Azacitidine, Cytarabine, Quizartinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 5, 2025 · Synced Sep 2, 2026, 9:11 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome

NCT04128748
View directory record Official record
Conditions
Acute Myeloid Leukemia, Blasts More Than 10 Percent of Bone Marrow Nucleated Cells, High Risk Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome
Interventions
Liposome-encapsulated Daunorubicin-Cytarabine, Quizartinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 2, 2026, 9:11 PM EDT
Terminated Phase 1 Interventional Results available

Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML)

NCT03552029
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Quizartinib, Milademetan
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
8
States / cities
Los Angeles, California • New Haven, Connecticut • Fairway, Kansas + 5 more
Source: ClinicalTrials.gov public record
Updated May 19, 2022 · Synced Sep 2, 2026, 9:11 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia

NCT03735875
View directory record Official record
Conditions
Acute Myeloid Leukemia With FLT3/ITD Mutation, Recurrent Acute Myeloid Leukemia, Refractory Acute Leukemia
Interventions
Quizartinib, Venetoclax
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 2, 2026, 9:11 PM EDT
Completed No phase listed Observational

Developing and Treating a Mouse Model of Acute Myeloid Leukemia Using Tissue Samples From Younger Patients With Acute Myeloid Leukemia

NCT01576185
View directory record Official record
Conditions
Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies
Interventions
laboratory biomarker analysis, quizartinib, sorafenib tosylate
Other · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Monrovia, California
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Sep 2, 2026, 9:11 PM EDT
Completed Phase 2 Interventional Results available

Efficacy Study for AC220 to Treat Acute Myeloid Leukemia (AML)

NCT00989261
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Compound AC220
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 85 Years
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
20
States / cities
San Francisco, California • Chicago, Illinois • Indianapolis, Indiana + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2019 · Synced Sep 2, 2026, 9:11 PM EDT
Completed Phase 1 Interventional Results available

AC220 for Children With Relapsed/Refractory ALL or AML

NCT01411267
View directory record Official record
Conditions
Lymphoblastic Leukemia, Acute, Childhood, Myelogenous Leukemia, Acute, Childhood
Interventions
AC220, Cytarabine, Etoposide, Methotrexate
Drug
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Other
Eligibility
1 Month to 21 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
11
States / cities
Los Angeles, California • Madera, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2022 · Synced Sep 2, 2026, 9:11 PM EDT
Recruiting Phase 1Phase 2 Interventional

Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

NCT03661307
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia
Interventions
Decitabine, Quizartinib, Venetoclax
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 2, 2026, 9:11 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations

NCT04493138
View directory record Official record
Conditions
Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Recurrent Myeloproliferative Neoplasm
Interventions
Azacitidine, Quizartinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 2, 2026, 9:11 PM EDT
Completed Phase 3 Interventional Results available

Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)

NCT02668653
View directory record Official record
Conditions
Acute Myeloid Leukemia, Leukemia
Interventions
Chemotherapy, Quizartinib, Placebo
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 75 Years
Enrollment
539 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
11
States / cities
Gainesville, Florida • Chicago, Illinois • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Sep 2, 2026, 9:11 PM EDT
Completed Phase 2 Interventional Results available

Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT01565668
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
AC220
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
18
States / cities
Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2019 · Synced Sep 2, 2026, 9:11 PM EDT
Completed Phase 1 Interventional

A Study of AC220 Given After Transplant in Subjects With Acute Myeloid Leukemia (AML)

NCT01468467
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
AC220
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
5
States / cities
Duarte, California • Chicago, Illinois • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2019 · Synced Sep 2, 2026, 9:11 PM EDT
Completed Phase 1 Interventional

Dose Finding, Safety and Tolerability Study for AC220 to Treat Advanced Solid Tumors

NCT01049893
View directory record Official record
Conditions
Solid Tumors
Interventions
Compound AC220
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2019 · Synced Sep 2, 2026, 9:11 PM EDT